Evidence map›Paper›PMID 29573193›Full record

ArticleCancer medicine2018

Importance of the site of positive surgical margin in salvage external beam radiation therapy for biochemical recurrence of prostate cancer after radical prostatectomy.

Tairo Kashihara, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Koji Inaba, Rei Umezawa, Satoshi Shima, Keisuke Tsuchida, Kazuma Kobayashi, Kana Takahashi and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Tairo KashiharaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-2471-605X
Satoshi NakamuraDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Akihisa WakitaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroyuki OkamotoDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Koji InabaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Rei UmezawaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Satoshi ShimaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Keisuke TsuchidaDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kazuma KobayashiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kana TakahashiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Naoya MurakamiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yoshinori ItoDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroyuki FujimotoDepartment of Urological Oncology, National Cancer Center Hospital, Tokyo, Japan.
Takashi UnoDepartment of Radiology, Chiba University Hospital, Chiba, Japan.
Jun ItamiDepartment of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tokyo National Hospital · JPChiba University Hospital · JPNational Cancer Centre Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to examine long-term outcomes in patients who received salvage radiotherapy (SRT) for biochemical recurrence (BRec) of prostate cancer after radical prostatectomy (RP). One hundred and twenty patients with prostate cancer who underwent SRT for BRec after RP without evidence of clinical disease were identified in our institution from 2002 to 2014. Prescription doses to prostate beds were 64.8 Gy with a fractional dose of 1.8 Gy in 96.7% of the patients. In three-dimensional conformal radiation therapy (3D-CRT), the seminal vesicle bed (SVB) was not included in the radiation fields. The prognostic factors for BRec-free survival (BRFS) and incidence of acute and late toxicities were investigated. Median follow-up duration after SRT was 64.9 months. The 5-year rates of BRFS, overall survival (OS), cause-specific survival (CSS), and clinical recurrence-free survival (CRFS) were 39.2%, 98.3%, 97.0%, and 91.9%, respectively. Only two patients experienced late grade 3 toxicity of hematuria. Multivariate analysis revealed that BRFS was significantly favorable in patients with prostate-specific antigen (PSA) values <0.5 ng/mL at the initiation of SRT and pathological Gleason score not including Gleason grade 5. In patients treated with 3D-CRT, a positive surgical margin at the base of the prostate influenced BRFS unfavorably in comparison with positive surgical margins at other sites. SRT for patients with BRec after RP was performed very safely in our institution. However, to improve BRFS, adequate inclusion of the SVB appears mandatory, especially in cases of positive surgical margins at the base of the prostate.

Indexed as

AgedDose Fractionation, RadiationHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, ConformalRadiotherapy DosageRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeProstate-Specific Antigenirradiation fieldProstate cancersalvage radiotherapy

Identifiers

PMID29573193
PMCPMC5943427
OpenAlexW2789306641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.